Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when STRO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSutro Biopharma terminates ATM equity program, reports 2025 financial results
Filed March 23, 2026 · Period ending March 23, 2026 · ~1 min read
Key Changes
-
medium
Sutro and Jefferies mutually terminated the at-the-market equity offering agreement effective March 23, 2026. The company can no longer issue additional shares under this facility, which had been in place since April 2021.
Item 1.02 verify on EDGAR → -
medium
The company announced full-year 2025 financial results via press release on March 23, 2026. Actual financial figures and performance metrics are contained in the attached press release, not in the 8-K body.
Item 2.02 verify on EDGAR →
Summary
Sutro Biopharma disclosed two events on March 23, 2026. First, the biotech company and investment bank Jefferies mutually ended their at-the-market equity offering program that had allowed Sutro to sell shares directly into the market since 2021. This removes one funding mechanism the company previously had available, though the mutual nature suggests it was a planned decision rather than forced by circumstances.
Second, Sutro released its full-year 2025 financial results through a standard earnings announcement. Retail investors should review the attached press release for the actual financial performance data, including revenue, cash position, and pipeline updates. Watch for management commentary on alternative funding strategies now that the ATM program is closed, and whether the company has sufficient cash runway for its clinical programs.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 23, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.
Sutro Biopharma disclosed its full-year 2025 financial results through a press release on March 23, 2026. The 8-K itself does not contain the actual financial figures; those are in the attached press release (Exhibit 99.1). This is a standard earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Sutro Biopharma filed an 8-K attaching a press release disclosing financial results for the year ended December 31, 2025.
Added in current filing · verify on EDGAR →
Press release issued by Sutro Biopharma, Inc. regarding its financial results for the year ended December 31, 2025, dated March 23, 2026.
The company filed an 8-K to announce the issuance of a press release containing its full-year 2025 financial results. This is a routine disclosure mechanism for earnings announcements. The actual financial details and performance metrics would be contained in the attached press release (Exhibit 99.1), which is not included in this 8-K body text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify